This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
High glucose: activates delta and beta cells, inhibits alpha cells. Low glucose: silences delta and beta cells, activates alpha cells. Glucagon: enhances glucose-induced secretion in beta cells. Insulin: indirectly (possibly, via delta cells) attenuates secretion in alpha cells. Somatostatin: inhibits alpha cells and beta cells. Also inhibits the secretion of pancreatic polypeptide. A large number of G protein-coupled receptors (GPCRs) regulate the secretion of insulin, glucagon, and somatostatin from pancreatic islets, and some of these GPCRs are the targets of drugs used to treat type-2 diabetes (ref GLP-1 receptor agonists, DPPIV inhibitors).
==== Musculoskeletal ==== Nonsteroidal anti-inflammatory drugs (NSAIDs) may be used to treat musculoskeletal symptoms. For individuals with severe complications, corticosteroids or immunosuppressive drugs may be prescribed, and sometimes intravenous immunoglobulins. Also, disease-modifying antirheumatic drugs, such as methotrexate, may be helpful. Hydroxychloroquine (Plaquenil) is another option and is generally considered safer than methotrexate. However, these prescribed drugs have a range of side effects such as nausea, loss of appetite, dizziness, hair loss, stomach aches/cramps, headache, liver toxicity and increased risk of infections.
Xanthoria parietina hosts a diverse array of lichenicolous fungi—fungi that live on lichens. As of 2017, at least 41 species of lichenicolous fungi have been reported on X. parietina, including both obligate parasites and facultative colonizers. Examples include Athelia arachnoidea, Catillaria nigroclavata, and Capronia suijae. While some of these fungi may be pathogenic, others colonize the lichen without causing obvious damage to the thallus. In some cases, multiple lichenicolous and saprotrophic fungi can form complex communities on decaying thalli of X. parietina. One study in Austria documented ten different fungal species simultaneously colonizing damaged lichen thalli. The most visually apparent was Xanthoriicola physciae, while the dematiaceous hyphomycete Cladosporium macrocarpum was the most abundant colonizer, covering large areas of the thallus and apothecia with dark cottony filaments. This fungus causes visible discoloration and unevenness of the apothecial discs before eventually destroying the lichen structure. Other notable parasites included Lichenoconium xanthoriae, Lichenodiplis poeltii, and Pyrenochaeta xanthoriae. The highly destructive Marchandiomyces aurantiacus forms distinctive pale orange crumbles on the lichen surface, ultimately shrinking the thallus to a bleached, fragile film that clings to the substrate before complete decay.
== Personal life == Springer is a gongshi collector. Springer is married to Chafen Lu, a former assistant professor at Harvard Medical School and an alumnus of his lab. He has five children, three from his first marriage.
==== Patrilineal DNA ==== Typical Y-DNA haplogroups of present-day Han Chinese include Haplogroup O-M95, Haplogroup O-M122, Haplogroup O-M175, Haplogroup C-M130, Haplogroup N-M231 and Haplogroup Q-M120. The Y-chromosome haplogroup distribution between Southern Han Chinese and Northern Han Chinese populations and principal core component analysis indicates that almost all modern Han Chinese populations form a tight cluster in their Y chromosome:
Sources: en.wikipedia.org
While it is usually considered that the driver has the responsibility when collisions occur, vehicle can also contribute to collisions, up to 3% to 5% of crashes. Two kinds of programs exist: new car assessment program for new cars, and vehicle inspections for other ones. A New Car Assessment Program is a government or institutional car safety program tasked with evaluating new car designs for performance against various safety threats. Two well known NCAP are United States New Car Assessment Program since 1978 and European New Car Assessment Programme since 1997.
Alternative splicing is one of the most important components that show functional complexity of genome. Modified splicing has significant effect on the phenotype that is relevance to disease or drug metabolism. A change in splicing can be caused by modifying any of the components of the splicing machinery such as splice sites or splice enhancers or silencers. Modification in the alternative splicing site can lead to a different protein form which will show a different function. Humans use an estimated 100,000 different proteins or more, so some genes must be capable of coding for a lot more than just one protein. Alternative splicing occurs more frequently than was previously thought and can be hard to control; genes may produce tens of thousands of different transcripts, necessitating a new gene model for each alternative splice.
The Valve Index is a discontinued virtual reality headset created and manufactured by Valve. Announced on April 30, 2019, it was released on June 28 of the same year. The Index is a second-generation headset and the first to be fully manufactured by Valve. Half-Life: Alyx is bundled with the headset. In November 2025, Valve announced a successor, the Steam Frame, scheduled for launch in early 2026.
Sanofi's application was considered by the same Endocrinologic and Metabolic Drugs Advisory FDA Committee that was considering lixisenatide as a single agent. In May 2016 by a vote of 12–2, with several members of the committee expressing reservations about Sanofi's plans to offer two pens with different ratios of insulin glargine and lixisenatide - one for people who had never taken insulin before and one for people who had; there was also concern about how to handle dosing when switching people from a single drug regimen to the combination drug. In August 2016 the FDA told Sanofi that it was delaying a final decision for three months, and asked Sanofi for more data on how people used the delivery devices. In November 2016, the FDA approved Sanofi's Soliqua formulation (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL). Soliqua became available in American pharmacies in January 2017.
The US Navy has actively participated in the Saudi-led naval blockade of Houthi-controlled territory in Yemen, which humanitarian organizations argue has been the main contributing factor to the outbreak of famine in Yemen. The four-month long Battle of Aden (2015) occurred between 25 March 2015 and 22 July. According to a 2015 September report by Esquire magazine, the Houthis, once the outliers, are now one of the most stable and organised social and political movements in Yemen. The power vacuum created by Yemen's uncertain transitional period has drawn more supporters to the Houthis. Many of the formerly powerful parties, now disorganised with an unclear vision, have fallen out of favour with the public, making the Houthis—under their newly branded Ansar Allah name—all the more attractive. Houthi spokesperson Mohamed Abdel Salam stated that his group had spotted messages between the UAE and Saleh three months before his death. He told Al-Jazeera that there was communication between Saleh, UAE and a number of other countries such as Russia and Jordan through encrypted messages. The alliance between Saleh and the Houthi broke down in late 2017, with armed clashes occurring in Sanaa from 28 November. Saleh declared the split in a televised statement on 2 December, calling on his supporters to take back the country and expressed openness to a dialogue with the Saudi-led coalition. On 4 December 2017, Saleh's house in Sanaa was assaulted by fighters of the Houthi movement, according to residents. Saleh was killed by the Houthis on the same day.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.